These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 25030731

  • 1. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T, Lingying W, Manni H, Jusheng A, Ning L.
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
    Kim TE, Park BJ, Kwack HS, Kwon JY, Kim JH, Yoon SC.
    J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q, Tu YQ, Chen JH, Lyu XJ, Yan DD.
    Zhonghua Zhong Liu Za Zhi; 2018 Jun 23; 40(6):462-466. PubMed ID: 29936774
    [Abstract] [Full Text] [Related]

  • 6. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
    Li X, Wei LC, Zhang Y, Zhao LN, Li WW, Ping LJ, Dang YZ, Hu J, Shi M.
    Int J Gynecol Cancer; 2016 Oct 23; 26(8):1472-9. PubMed ID: 27400321
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H, Tsujino K, Sulaiman NS, Sekii S, Matsumoto Y, Ota Y, Soejima T, Yamaguchi S, Sasaki R.
    Radiat Oncol; 2019 Dec 26; 14(1):236. PubMed ID: 31878944
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
    Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, Yeo R, Ho TH, Tay EH, Chia YN, Soh LT, Khoo-Tan HS.
    Int J Gynecol Cancer; 2010 Apr 26; 20(3):428-33. PubMed ID: 20375809
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY, Huang YJ, Chanchien CC, Lin H, Wang CJ, Sun LM, Tseng CW, Tsai CC, Ou YC, Fu HC, Chen HC, Hsu HC, Wang CY.
    Radiat Oncol; 2012 Jan 30; 7():13. PubMed ID: 22289572
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.